| scholarly article | Q13442814 |
| P2093 | author name string | Mark Greenwood | |
| Kory Johnson | |||
| Bibiana Bielekova | |||
| Ann Marie Weideman | |||
| Marco Aurelio Tapia-Maltos | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 |
| T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions | Q24562400 | ||
| Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis | Q24635370 | ||
| Neurotoxic reactive astrocytes are induced by activated microglia | Q33602850 | ||
| A complex role of herpes viruses in the disease process of multiple sclerosis | Q34078589 | ||
| Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis | Q34295012 | ||
| Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis | Q34300614 | ||
| The (mis)use of overlap of confidence intervals to assess effect modification | Q34940220 | ||
| NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury | Q35776944 | ||
| Reduced cortical microvascular oxygenation in multiple sclerosis: a blinded, case-controlled study using a novel quantitative near-infrared spectroscopy method | Q36275414 | ||
| Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis | Q36613394 | ||
| Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis | Q36639659 | ||
| Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis | Q37398059 | ||
| Will the real multiple sclerosis please stand up? | Q38020092 | ||
| Progressive multiple sclerosis: pathology and pathogenesis | Q38046113 | ||
| Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. | Q39025444 | ||
| Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis | Q40400256 | ||
| Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. | Q40431316 | ||
| Pharmacodynamic effects of daclizumab in the intrathecal compartment | Q40962441 | ||
| Natural history of multiple sclerosis: a unifying concept | Q42678110 | ||
| A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. | Q42847184 | ||
| Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. | Q43241664 | ||
| Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study | Q47916199 | ||
| Efficient central nervous system remyelination requires T cells | Q47933086 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions | Q48301218 | ||
| "Tissue-repairing" blood-derived macrophages are essential for healing of the injured spinal cord: from skin-activated macrophages to infiltrating blood-derived cells? | Q48311169 | ||
| Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. | Q48427388 | ||
| Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis | Q48648706 | ||
| Age at disability milestones in multiple sclerosis | Q48686550 | ||
| Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis | Q49072224 | ||
| The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. | Q51648841 | ||
| Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. | Q51843807 | ||
| Sustained reduction of MS disability | Q57601793 | ||
| P4510 | describes a project that uses | RStudio | Q4798119 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 577 | |
| P577 | publication date | 2017-11-10 | |
| P1433 | published in | Frontiers in Neurology | Q15817039 |
| P1476 | title | Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments | |
| P478 | volume | 8 |
| Q64066343 | A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients |
| Q63352419 | Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme |
| Q90544282 | Cerebrospinal fluid biomarkers link toxic astrogliosis and microglial activation to multiple sclerosis severity |
| Q63406317 | Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis |
| Q90322472 | Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS |
| Q58756156 | Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience |
| Q92992556 | Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS |
| Q64103593 | Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study |
| Q89999379 | Epidemiology and treatment of multiple sclerosis in elderly populations |
| Q60046191 | Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland |
| Q92239438 | Immunological Aspects of Approved MS Therapeutics |
| Q99238231 | Impact of Repetitive Transcranial Magnetic Stimulation on Neurocognition and Oxidative Stress in Relapsing-Remitting Multiple Sclerosis: A Case Report |
| Q64249921 | Inflammatory activity and vitamin D levels in an MS population treated with rituximab |
| Q59355260 | Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects |
| Q91867962 | Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis |
| Q63246385 | Local Antigen Encounter Is Essential for Establishing Persistent CD8 T-Cell Memory in the CNS |
| Q92037637 | Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials |
| Q93271342 | Multiple Sclerosis Medications in the VHA: Delivering Specialty, High-Cost, Pharmacy Care in a National System |
| Q45974017 | New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability. |
| Q92802794 | Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis |
| Q55108719 | Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials. |
| Q92057928 | Relapse recovery: The forgotten variable in multiple sclerosis clinical trials |
| Q90559071 | Rethinking multiple sclerosis treatment strategies |
| Q91936614 | Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials |
| Q61449544 | The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses |
| Q57815075 | The topographical model of MS: Empirical evaluation of the recapitulation hypothesis |
Search more.